Literature DB >> 9196121

Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose.

E C Adam1, B S Mitchell, D U Schumacher, G Grant, U Schumacher.   

Abstract

Respiratory tract infection by Pseudomomas aeruginosa may be life-threatening for intensive care patients and patients with cystic fibrosis (CF). The colonization of airways can be facilitated by bacterial lectins (carbohydrate-binding proteins) that attach bacteria to the glycoconjugates of the mucosa. We show in this paper that the fucose-specific lectin P. aeruginosa agglutinin II (PAII) produced by these bacteria can, in addition to facilitating bacterial adhesion, arrest ciliary beating in human airways in vitro. This inhibitory effect of the lectin can be abolished by preincubating PAII with its specific sugar, fucose. Furthermore, ciliary beating is completely restored by addition of fucose 2 h after administration of PAII to cell cultures. Therefore, adding a simple monosaccharide to nebulizers may improve the management of P. aeruginosa infection by abrogating the effect of PAII on ciliary beating, thus restoring part of the nonspecific pulmonary defense mechanisms of the airways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196121     DOI: 10.1164/ajrccm.155.6.9196121

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

1.  Local administration of 2% trimecaine affects the content of fucosylated glycoconjugates in goblet cells in rabbit tracheal epithelium.

Authors:  Ludek Vajner; Jirí Uhlík; Václava Konrádová; Andrea Klescová; Jana Adásková
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

Review 2.  Biofilm Matrix Proteins.

Authors:  Jiunn N C Fong; Fitnat H Yildiz
Journal:  Microbiol Spectr       Date:  2015-04

3.  The Pseudomonas aeruginosa lectins PA-IL and PA-IIL are controlled by quorum sensing and by RpoS.

Authors:  K Winzer; C Falconer; N C Garber; S P Diggle; M Camara; P Williams
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

4.  Inhibition of the bacterial lectins of Pseudomonas aeruginosa with monosaccharides and peptides.

Authors:  H Gustke; R Kleene; G Loers; N Nehmann; M Jaehne; K-M Bartels; K-E Jaeger; M Schachner; U Schumacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-22       Impact factor: 3.267

5.  Terminal glycosylation of cystic fibrosis airway epithelial cells.

Authors:  A D Rhim; V A Kothari; P J Park; A E Mulberg; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

Review 6.  Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell.

Authors:  A D Rhim; L Stoykova; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

7.  Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia.

Authors:  Iwona Bucior; Jason Abbott; Yuanlin Song; Michael A Matthay; Joanne N Engel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-06-21       Impact factor: 5.464

Review 8.  Terminal glycosylation and disease: influence on cancer and cystic fibrosis.

Authors:  T F Scanlin; M C Glick
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

9.  Glycosylation is required for outer membrane localization of the lectin LecB in Pseudomonas aeruginosa.

Authors:  Kai-Malte Bartels; Horst Funken; Andreas Knapp; Melanie Brocker; Michael Bott; Susanne Wilhelm; Karl-Erich Jaeger; Frank Rosenau
Journal:  J Bacteriol       Date:  2011-01-07       Impact factor: 3.490

10.  The first engagement of partners in the Euprymna scolopes-Vibrio fischeri symbiosis is a two-step process initiated by a few environmental symbiont cells.

Authors:  Melissa A Altura; Elizabeth A C Heath-Heckman; Amani Gillette; Natacha Kremer; Anne-Marie Krachler; Caitlin Brennan; Edward G Ruby; Kim Orth; Margaret J McFall-Ngai
Journal:  Environ Microbiol       Date:  2013-07-03       Impact factor: 5.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.